Back

APOE ε4 allele advances the age-dependent decline of amyloid β clearance in the human cortex

Saito, A.; Kageyama, Y.; Pletnikova, O.; Rudow, G. L.; An, Y.; Irie, Y.; Kita, A.; Miki, K.; Li, L.; Southall, P.; Irie, K.; Troncoso, J. C.

2021-04-08 pathology
10.1101/2021.04.07.438832 bioRxiv
Show abstract

IntroductionOur previous study indicated that the pericapillary clearance of amyloid {beta} (A{beta}) declines with age in APOE 3/3 subjects. Here, we examine whether the APOE {varepsilon}4 allele has an impact on this age-related decline. MethodsWe examined 69 autopsy brains of APOE {varepsilon}3/{varepsilon}4 or APOE {varepsilon}3/{varepsilon}3 individuals (30-65 years) for the immunohistochemical localization of intracellular, extracellular, and pericapillary A{beta} in the cerebral cortex. ResultsIn APOE {varepsilon}3/{varepsilon}4 individuals, the percentage of A{beta} positive pericapillary spaces began to decrease (p=0.030), and the number of extracellular A{beta} particles increased in the early 30s (p=0.0008). Those average values were significantly lower (p<0.0001) and higher (p<0.0001), respectively, compared to APOE {varepsilon}3/{varepsilon}3 individuals. DiscussionOur observations indicate that APOE {varepsilon}4 allele advances by one decade at the onset of age-related decline in A{beta} glymphatic clearance. This finding supports early clinical intervention and stratification by APOE genotype to prevent A{beta} deposition and AD progression.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.